Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 197

The DOI matches its Crossref record.

Mass-Spectrometric Identification of a Novel Angiotensin Peptide in Human Plasma

Jankowski, Vera, Vanholder, Raymond, van der Giet, Markus, Tölle, Markus, Karadogan, Sevil, Gobom, Johan, Furkert, Jens, Oksche, Alexander, Krause, Eberhard, Anh Tran, Thi Nguyet, Tepel, Martin, Schuchardt, Mirjam, Schlüter, Hartmut, Wiedon, Annette, Beyermann, Michael, Bader, Michael, Todiras, Mihail, Zidek, Walter, Jankowski, Joachim·2007·Arteriosclerosis, Thrombosis, and Vascular Biology

Abstract

Objective—Angiotensin peptides play a central role in cardiovascular physiology and pathology. Among these peptides, angiotensin II (Ang II) has been investigated most intensively. However, further angiotensin peptides such as Ang 1-7, Ang III, and Ang IV also contribute to vascular regulation, and may elicit additional, different, or even opposite effects to Ang II. Here, we describe a novel Ang II-related, strong vasoconstrictive substance in plasma from healthy humans and end-stage renal failure patients. Methods and Results—Chromatographic purification and structural analysis by matrix-assisted laser desorption/ionisation time-of-flight/time-of-flight (MALDI-TOF/TOF) revealed an angiotensin octapeptide with the sequence Ala-Arg-Val-Tyr-Ile-His-Pro-Phe, which differs from Ang II in Ala 1 instead of Asp 1. Des[Asp 1]-[Ala 1]-Ang II, in the following named Angiotensin A (Ang A), is most likely generated enzymatically. In the presence of mononuclear leukocytes, Ang II is converted to Ang A by decarboxylation of Asp 1. Ang A has the same affinity to the AT 1 receptor as Ang II, but a higher affinity to the AT 2 receptor. In the isolated perfused rat kidney, Ang A revealed a smaller vasoconstrictive effect than Ang II, which was not modified in the presence of the AT2 receptor antagonist PD 123319, suggesting a lower intrinsic activity at the AT 1 receptor. Ang II and Ang A concentrations in plasma of healthy subjects and end-stage renal failure patients were determined by matrix-assisted laser desorption/ionisation mass-analysis, because conventional enzyme immunoassay for Ang II quantification did not distinguish between Ang II and Ang A. In healthy subjects, Ang A concentrations were less than 20% of the Ang II concentrations, but the ratio Ang A / Ang II was higher in end-stage renal failure patients. Conclusion—Ang A is a novel human strong vasoconstrictive angiotensin-derived peptide, most likely generated by enzymatic transformation through mononuclear leukocyte-derived aspartate decarboxylase. Plasma Ang A concentration is increased in end-stage renal failure. Because of its stronger agonism at the AT 2 receptor, Ang A may modulate the harmful effects of Ang II.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/01.atv.0000253889.09765.5f

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 197

Metadata

Authors
Jankowski, V., Vanholder, R., van der Giet, M., Tölle, M., Karadogan, S., Gobom, J., Furkert, J., Oksche, A., Krause, E., Anh Tran, T. N., Tepel, M., Schuchardt, M., Schlüter, H., Wiedon, A., Beyermann, M., Bader, M., Todiras, M., Zidek, W., & Jankowski, J.
Venue
Arteriosclerosis, Thrombosis, and Vascular Biology
Published
2007-02
Volume
27
Issue
2
Pages
297-302
ISSN
  • 1079-5642 (ISSN-L)
  • 1524-4636
OpenAlex
W2115329764
Cited by
197
References
0
FWCI
3.72
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Mass-Spectrometric Identification of a Novel Angiotensin Peptide in Human Plasma. https://app.cochat.ai/papers/10.1161/01.atv.0000253889.09765.5f
The paper
Jankowski, V., Vanholder, R., van der Giet, M., Tölle, M., Karadogan, S., Gobom, J., Furkert, J., Oksche, A., Krause, E., Anh Tran, T. N., Tepel, M., Schuchardt, M., Schlüter, H., Wiedon, A., Beyermann, M., Bader, M., Todiras, M., Zidek, W., & Jankowski, J. (2007). Mass-Spectrometric Identification of a Novel Angiotensin Peptide in Human Plasma. Arteriosclerosis, Thrombosis, and Vascular Biology. https://doi.org/10.1161/01.atv.0000253889.09765.5f

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.